
KAEF
Detail Analisis & Profil Saham
Deep AI Analysis
AI sedang menyusun analisis mendalam untuk KAEF...
Analisis AI Belum Tersedia
Klik tombol "Perbarui Analisis" di atas untuk men-generate analisis teknikal dan fundamental secara instan.
Tentang Perusahaan
PT Kimia Farma Tbk, together with its subsidiaries, manufactures and sells a range of medicines in Indonesia and internationally. It operates through Manufacture, Distribution, Retail, and Others segments. The company offers drugs in the form of tablets, effervescent tablets, hard and soft capsules, liquids, syrups, oral powders, non-beta-lactam external liquids, beta-lactam tablets and dry syrups, injections, ointments, creams, suppositories, semisolid dosage forms, and health supplements; traditional medicines; generic drugs, such as paracetamol, amoxicillin, and omeprazole; ethical products; over-the-counter products and herbs; and narcotic drugs and psychotropics. It also provides health food; cosmetics; edible, castor, and essential oils; active pharmaceutical ingredients and high-function chemicals; quinine salt and its derivatives; antiseptic solutions; stem cells; and medical devices. In addition, the company engages in the provision of integrated health services, including pharmacies, health and beauty clinics, clinical and diagnostic laboratories, and optics; pharmacy retail management; and distribution of medicines to pharmacies, hospital pharmacies, medical centers, and drug stores, as well as cosmetics and medical devices. It exports its products to Asia, Europe, Australia, Africa, and America. The company was founded in 1817 and is headquartered in Jakarta Pusat, Indonesia. PT Kimia Farma Tbk operates as a subsidiary of PT. Bio Farma.
Jajaran Direksi
Struktur Kepemilikan
Valuasi Utama
Data Keuangan & Metrik
Indikator Momentum
Volume & Tren MA
Berita Terkini
Emiten BUMN mulai turnaround, analis: prospek membaik tapi belum sepenuhnya solid
Kimia Farma (KAEF) kaji putusan arbitrase Rp 2,2 triliun, DPR soroti tata kelola BUMN
Bikin Rugi Rp 1,82 Triliun, Audit Investigasi Kimia Farma Apotek Rampung Agustus
Kimia Farma Cetak Rugi Rp 1,82 Triliun di 2023, Ini Penyebabnya
Kimia Farma Teken Perjanjian Pengalihan Saham dengan AII dan CIZJ
Saham Kimia Farma Melonjak 12 Persen Meski Vaksin Berbayar Ditunda
Saham KAEF 10 Hari Anjlok Kena ARB, Kok Nggak Disuspensi?
Saham KAEF Sudah Kelewat Mahal, Hati-hati buat yang Megang
Euforia Uji Klinis Bio Farma, Saham INAF dan KAEF Kena Auto Rejection
Tidak ada berita Nasional terbaru.
Tidak ada berita Global terbaru.